Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

• the present invention relates to novel xanthine derivatives having potent pharmacological activity and intermediates for the preparation thereof. More particularly, the present invention relates to compounds having potent angiotensin II antagonist activity and hypotensive activity, which are useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.
• the renin-angiotensin system is involved in the homeostatic function to control systemic blood pressure, the volume of body fluid, balance among the electrolytes, etc., associated with the aldosterone system.
• Development of angiotensin II converting enzyme inhibitors (ACE inhibitor) (this converting enzyme produces angiotensin II which possesses strong vasoconstrictive activity) has clarified the relation between the renin-angiotensin system and hypertension. Since angiotensin II elevates blood pressure via the angiotensin II receptors on cell membranes, angiotensin II antagonists as well as the ACE inhibitor would be useful in treating hypertension.
• angiotensin II analogues such as saralasin, [Sar 1 ,Ile 8 ]A II, and the like, possess potent angiotensin II antagonist activity.
• Non-peptide angiotensin II antagonists are disclosed in Japanese Patent Laid Open No. 71073/1981; No. 71074/1981; No. 92270/1982; No. 157768/1983; No. 240683/1987; No. 23868/1988; and No. 11787/1989, EP Laid Open No. 0323841, etc.
• Imidazole derivatives having angiotensin II antagonist activity are disclosed in A. T. Chiu et al., Eur. J. Pharm., 157, 13 (1981), P. C. Wong et al., J. Pharmcol. Exp. Ther., 247, 1 (1988), P. C. Wong et al., Hypertension, 13, 489 (1989), etc.
• the present inventors made extensive investigations to prepare useful compounds which have angiotensin II antagonist activity. As a result of these researches, the present inventors have succeeded in synthesizing xanthine derivatives possessing excellently potent angiotensin II antagonist activity and developed their work to accomplish the present invention.
• the present invention provides xanthine derivatives having the formula 1: wherein R' , which may be optionally bound through a hetero atom, is a hydrocarbon residue which may be substituted; one of R 2 and R 3 is a hydrocarbon residue which may be substituted, and the other is hydrogen or a hydrocarbon residue which may be substituted; R 4 is hydrogen, halogen or nitro; R 5 is a residue capable of forming an anion or a residue convertible into the anion; A is a direct bond or a spacer having atomic length of two or less; n is an integer of 1 or 2; and Y and Z, which may be the same or different, are an oxygen atom or a sulfur atom; and the pharmaceutically acceptable salts thereof.
• hydrocarbon residues for R' include acyclic hydrocarbon residues such as lower alkyl of 1 to about 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, and the like), lower alkenyl of 2 to about 8 carbon atoms (e.g.
• cyclopropyl cyclopentyl, cyclohexyl, 2-cyclohexen-1-yl, cyclooctyl, and the like
• aromatic hydrocarbon residues 6 to about 12 carbon atoms (e.g. phenyl, naphtyl, and the like); and the like.
• hydrocarbon residues for R' may be bound to a xanthine nucleus through a hetero atom selected from S, 0, and NR wherein R is hydrogen or a hydrocarbon residue which may be substituted and optionally substituted with hydroxyl, lower (C 1-4 ) alkoxy (e.g. methoxy, ethoxy, and the like), lower (Ci- 4 ) alkyl (e.g. methyl, ethyl, and the like), halogen (e.g. F, Cl, Br and the like), nitro, amino which may be optionally substituted (e.g. amino, and the like), acyloxy (e.g.
• hydrocarbon residues include lower alkyl of 1 to about 8 carbon atoms which may be bound to a xanthine nucleus through a sulfur atom, lower alkyl of 1 to about 4 carbon atoms substituted with phenyl which may be optionally substituted with halogen, nitro, lower (C 1-4 ) alkoxy, lower (C I - 4 ) alkyl or the like at an optional position on the phenyl ring (e.g.
• phenyl-lower (C 1-4 ) alkyl such as benzyl, phenethyl, phenylpropyl, and the like
• phenyl which may be optionally substituted with halogen, nitro, lower (C 1-4 ) alkoxy, lower (C 1-4 ) alkyl, or the like at an optional position on the phenyl ring.
• hydrocarbon residues for R 2 and R 3 include acyclic hydrocarbon residues such as lower alkyl of 1 to about 4 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, and the like), lower alkenyl of 2 to about 4 carbon atoms (e.g. vinyl, allyl, isopropenyl, 2-butenyl, 1,3-butadienyl, and the like), lower alkynyl of 2 to about 4 carbon atoms (e.g.
• cyclic hydrocarbon residues such as alicyclic hydrocarbon residues of 3 to about 6 carbon atoms (e.g. cyclopropyl, cyclopentyl, cyclohexyl, 2-cyclohexen-1-yi, and the like), aromatic hydrocarbon residues of about 6 carbon atoms (e.g. phenyl, and the like); etc.
• Said hydrocarbon residues for R 2 and R 3 may be optionally substituted with hydroxyl, lower (C 1-4 ) alkoxy (e.g. methoxy, ethoxy, and the like), lower (C 1-4 ) alkyl (e.g. methyl, ethyl, and the like), halogen (e.g. F, Cl, Br and the like), nitro, amino which may be optionally substituted (e.g. amino, methylamino, dimethylamino, and the like), acyloxy (e.g. lower (C 1-4 ) alkanoyloxy, benzoyloxy and the like), phenyl (e.g. phenyl which may be optionally substituted with halogen, nitro, lower (C 1-4 ) alkoxy, lower (C 1 - 4 ) alkyl or the like at an optional position on the phenyl ring), etc.
• lower (C 1-4 ) alkoxy e.g. methoxy, e
• lower (C 1-4 ) alkyl of 1 to about 4 carbon atoms which may be optionally substituted with hydroxyl, lower (C 1-4 ) alkoxy, optionally substituted amino, acyloxy and the like
• lower alkyl of 1 to about 4 carbon atoms substituted with phenyl which may be optionally substituted with halogen, nitro, lower (C 1-4 ) alkoxy, lower (C 1-4 ) alkyl or the like at an optional position on the phenyl ring
• phenyl-lower (C 1-4 ) alkyl such as benzyl, phenethyl, phenylpropyl, and the like
• phenyl which may be optionally substituted with halogen, nitro, lower (C 1-4 ) alkoxy, lower (C 1-4 ) alkyl or the like at an optional position on the phenyl ring.
• More preferred examples of such hydrocarbon residues are lower alkyl of 1 to about 4 carbon atoms.
• R 4 represents hydrogen, halogen (e.g. Cl, Br and the like), or nitro and may be in the ortho or meta positions.
• a preferred example of R 4 is hydrogen.
• residues capable of forming an anion and residues convertible into the anion for R S include carboxyl, lower (C 1 - 4 ) alkoxycarbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide (-NHS0 2 CF 3 ,) , phosphoric acid, sulfonic acid, and the like and these groups are optionally protected with an optionally substituted lower alkyl group or acyl group as shown by R 6 and R 7 described below.
• residues may include those which are capable of forming anions either chemically or under biological and/or physiological conditions.
• R 5 may be in the ortho, meta or para position, and preferably in the ortho position. More preferred examples of R 5 are carboxyl and tetrazolyl.
• R 5 is a residue capable of forming an anion or convertible thereinto (e.g. cyano and the like) chemically are useful as synthetic intermediates.
• the group A represents a direct bond or a spacer having atomic length of two or less between a phenylene group and a phenyl group.
• the groups Y and Z are each an oxygen atom or a sulfur atom and may be the same or different. They are preferably the same and further an oxygen atom.
• a preferred embodiment of the invention is a compound of the formula (1') wherein R' , which may be optionally bound through a sulfur or oxygen atom, preferably a sulfur atom, is lower (C 1-8 ) alkyl, phenyl-lower (C 1-4 ) alkyl which may be optionally substituted or phenyl which may be optionally substituted; R 2 and R 3 are each lower (C 1-4 ) alkyl; and R 5 is carboxyl or tetrazolyl; and the pharmaceutically acceptable salts thereof.
• the compounds of the present invention may be prepared by several reaction schemes, as illustrated below for a preferred compound.
• R 1 , R 2 , R 3 , R 4 , R 5 , Z, Y, A, and n have the above-defined meanings and X is halogen.
• R', R 2 , R 3 , R 4 , Z, Y, A, and n have the above-defined meanings.
• R', R 2 , R 3 , R 4 , R 6 , Z, Y, A, and n have the above-defined meanings.
• R' , R 2 , R 3 , R 4 , R 7 , Z, Y, A, and n have the above-defined meanings.
• the reaction as illustrated in Scheme A is an alkylation using an alkylating agent in the presence of a base.
• One molar portion of the compound (II) is employed with 1 to 3 moles of the base and about 1 to about 3 moles of the alkylating agent.
• the reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethylmethylketone, and the like.
• bases include sodium hydride, potassium t-butoxide, potassium carbonate, sodium carbonate, and the like.
• alkylating agents include substituted halides (e.g. chlorides, bromides, iodides, and the like), substituted sulfonate esters (e.g. methyl p-toluenesulfonate esters, and the like), etc.
• reaction conditions may vary depending on the combination of the base and the alkylating agent.
• a temperature in the range of from ice-cooling to room temperature is preferred and a reaction period of from about 1 to about 10 hours is preferably employed.
• the cyano substituent on the benzene is reacted with various azides to form the tetrazole componds (1c) as illustrated in Scheme B.
• One molar portion of the compound (lb) is employed with about 1 to about 3 moles of the azide.
• the reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, toluene, benzene, and the like.
• examples of such azides include trialkyl-tin azide, triphenyl-tin azide, hydrogen azide, and the like.
• the organo-tin azide compound is employed, the reaction is carried out in toluene or benzene by heating under a reflux for a period of from about 10 to about 30 hours.
• reaction as illustrated in Scheme C is used to obtain the compound (le) by deprotection of the suitably protected tetrazole derivative (1d).
• Reaction conditions for the deprotection can vary with the protective group (R 6 ) employed.
• R 6 is triphenylmethyl, 2-tetrahydropyranyl, methoxymethyl, ethoxymethyl, etc.
• the reaction is preferably carried out in an aqueous alcohol (e.g. methanol, ethanol, etc.) containing about 0.5 N to about 2 N hydrochloric acid or acetic acid, at room temperature or near for a period from about 1 to about 10 hours.
• reaction as illustrated in Scheme D used is to obtain the compound (1g) by deprotection of the suitably protected carboxylic acid derivative (If).
• Deprotection conditions for the reaction can vary with the protective group (R 7 ) employed.
• R 6 is t-butyl
• the reaction is preferably carried out using an excess amount of trifluoroacetic acid in a suitable organic solvent (e.g. chloroform, methylene chloride, acetonitrile, etc.), at room temperature or near for a period from about 1 to about 5 hours.
• a suitable organic solvent e.g. chloroform, methylene chloride, acetonitrile, etc.
• the compounds (I) thus produced via the reaction processes as depicted in Schemes A, B, C and D can be isolated and purified from the reaction mixture according to conventional methods such as for example, evaporation of solvents, extraction by water or organic solvents, concentration, neutralization, recrystallization, distillation, column chromatography and the like, to obtain a crystalline or oily product.
• the compounds (I) of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases.
• These salts include but are not limited to the following: salts with inorganic acids such as hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, maleic acid.
• Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
• the starting materials (II) may be prepared by or according to methods described in, for example,
• the compounds (Illa) are prepared by methods described in Japanese Patent Laid Open No. 23868/1988; No. 117876/1989; and EP Laid Open No. 0323841. These compounds (ilia) can also be easily prepared from the compounds (IV) commercially available or synthesized by known methods, via halogenomethylation as illustrated in Scheme E, according to processes described in, for example, A. A. Vansheidt et al., Khim. Nauka i Prom., 2, 799 (1957), etc. Scheme E wherein each group has the above-defined meaning.
• the compounds (Illb) are prepared from the compounds (Illa) according to processes as illustrated in Scheme F.
• the compounds (I) and salts thereof according to the present invention inhibit strongly vasoconstriction and hypertension derived by angiotensin II and therefore possess potent anti-hypertensive activity in animals, more specifically e.g. humans, dogs, rabbits, rats, etc. Further, the compounds (I) and salts thereof according to the present invention are of quite low toxicity and useful in treating not only hypertension but also circulatory system diseases such as heart diseases, strokes and the like.
• the compounds (I) and salts thereof can be administered as pharmaceutical compositions (e,g, powders, granules, tablets, pills, capsules, injections, solutions) comprising at least one such compound alone or in admixture with pharmaceutically acceptable carriers, excipients and/or diluents.
• the pharmaceutical compositions can be formulated in accordance with a conventional method.
• the active ingredient When used for treating adult essential hypertension, the active ingredient will preferably be administered in an appropriate amount, for example, selected from the range of from about 10 mg to 100 mg a day orally and from the range of from about 5 mg to 50 mg a day intravenously. The active ingredient will preferably be administered in equal doses two or three times a day.
• 6-Amino-5-valerylamino-1,3-dimethyluracil (2.54 g, 10 mmoles) obtained in Reference Example 1-A was dissolved in a mixture of 1 N aqueous sodium hydroxide (40 ml) and ethanol (10 ml), and heated at reflux for 1.5 hours with stirring. To the reaction mixture was then added ethyl acetate and the resulting crystals were collected by filtration. The crystals were washed with water and then petroleum to obtain 2.54 g of the crystals. Recrystallization from ethanol gave the title compound (2.27 g, 96.1 %) as a colorless prism. M.p. 240-241 C. IR (Nujol) cm -1 : 3150, 1715.
• the compounds (I) of the present invention are employed, for example, when used as agents for treating circulatory system diseases such as hypertension, heart diseases, strokes and the like, in the following formulations.
• the ingredients (1 (2), and (3) and a half of the ingredient (4) were blended together and granulated. To this mixture was added the remaining half of the ingredient (4) and distributed into gelatine capsules.
• the ingredients (1 (2) and (3) were dissolved in distilled water for injection to a total volume of two ml and distributed into ampules. Total processes were carried out under sterile conditions.
• Inhibitory assay for the binding of angiotensin II to angiotensin receptor was conducted by modifying a method as described by Douglas et al. (Endocrinology, 102, 685-696 (1978)).
• Angiotensin II receptor membrane fractions were prepared from bovine adrenal cortex.
• the compound (I) of the present invention (10 -9 -3x10 -5 M) and 12 SI-angiotensin II ( 125 I-AII) (1.8kBq/50 ⁇ l) were added to the A II receptor membrane fraction and incubated at room temperature for one hour. The bound and free 125 I-AII were separated by a filter (Whatman GF/B filter) each other. The radioactivity of 125 I-All bound on the receptor was measured.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=18047088

Family Applications (1)

Country Status (2)

Cited By (33)

Citations (2)

• 1990
  • 1990-11-30 EP EP19900123013 patent/EP0430300A3/en not_active Withdrawn
  • 1990-12-03 CA CA 2031328 patent/CA2031328A1/fr not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events